Back to mobile site

More on PLRX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+11.6% Growth)
- Ratings (2.7 Score)

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Pliant Therapeutics Inc. (NQ:PLRX)
Delayed: 0.89 -0.02 (2.2%)
Prev. Close $0.91  
Open$0.93 
52 Wk High$ 
52 Wk Low$ 
Day High$0.93 
Day Low$0.89 
P/E N/A  
EPS$ 
Volume210,574 


Oct 20, 2026 08:30 AM Pliant Therapeutics names siRNA research veteran as SVP
Oct 20, 2026 08:30 AM Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Oct 19, 2026 04:05 PM Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Oct 2, 2026 04:20 PM Form 4 PLIANT THERAPEUTICS, For: Oct 01 Filed by: Raben David
Oct 2, 2026 04:19 PM Form 3 PLIANT THERAPEUTICS, For: Sep 30 Filed by: Raben David
Sep 30, 2026 04:10 PM Pliant Therapeutics names David Raben as chief medical officer
Sep 30, 2026 04:10 PM Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Aug 18, 2026 08:30 AM Pliant Therapeutics gets FDA Fast Track for PLN-101095 in solid tumors
Aug 18, 2026 08:30 AM Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Aug 14, 2026 09:31 PM Form SCHEDULE 13G PLIANT THERAPEUTICS, Filed by: ADAR1 Capital Management, LLC
View All Articles

Entities mentioned with PLRX

View All Entities